ulrich medical USA announced FDA 510(k) marketing clearance for expanded indications of the Momentum and Momentum MIS Posterior Spinal Fixation Systems. The indications allow for both systems to be used in conjunction with G21 V-STEADY Radiopaque Bone Cement to help restore the integrity of the spinal column in patients with advanced stage tumors.
The Momentum and Momentum MIS Posterior Spinal Fixation Systems are used to provide stabilization, fixation and correction of the thoracolumbar and sacroiliac spine. These fixation systems enable surgeons to manage a range of adult degenerative and deformity cases, including connections from occiput to pelvis, bone cement augmentation, and revisions for adjacent segment disease in restoration of spinal alignment in open or percutaneous procedures.
“We are pleased to have received this expanded indication from FDA”, said Eric Lucas, Ph.D., Vice President of Technology at ulrich medical USA. “The combination of Momentum with V-STEADY offers our surgeon customers a new treatment option to support their most challenging patients.”
ulrich medical USA announced FDA 510(k) marketing clearance for expanded indications of the Momentum and Momentum MIS Posterior Spinal Fixation Systems. The indications allow for both systems to be used in conjunction with G21 V-STEADY Radiopaque Bone Cement to help restore the integrity of the spinal column in patients with advanced stage...
ulrich medical USA announced FDA 510(k) marketing clearance for expanded indications of the Momentum and Momentum MIS Posterior Spinal Fixation Systems. The indications allow for both systems to be used in conjunction with G21 V-STEADY Radiopaque Bone Cement to help restore the integrity of the spinal column in patients with advanced stage tumors.
The Momentum and Momentum MIS Posterior Spinal Fixation Systems are used to provide stabilization, fixation and correction of the thoracolumbar and sacroiliac spine. These fixation systems enable surgeons to manage a range of adult degenerative and deformity cases, including connections from occiput to pelvis, bone cement augmentation, and revisions for adjacent segment disease in restoration of spinal alignment in open or percutaneous procedures.
“We are pleased to have received this expanded indication from FDA”, said Eric Lucas, Ph.D., Vice President of Technology at ulrich medical USA. “The combination of Momentum with V-STEADY offers our surgeon customers a new treatment option to support their most challenging patients.”
Copy to clipboard 
